A multi-center, non-interventional, prospective study of durvalumab in unresectable locally advanced NSCLC in routine clinical practice in Russia

Trial Identifier: D4194R00027
Sponsor: AstraZeneca
NCTID:: NCT05456867
Start Date: May 2022
Primary Completion Date: November 2026
Study Completion Date: November 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russia Arkhangelsk, Russia
Russia Chelyabinsk, Russia
Russia Ekaterinburg, Russia
Russia Grozny, Russia
Russia Irkutsk, Russia
Russia Kemerovo, Russia
Russia Khanty-Mansiysk, Russia
Russia Kostroma, Russia
Russia Krasnodar, Russia
Russia Krasnoyarsk, Russia
Russia Moscow, Russia
Russia Murmansk, Russia
Russia N.Novgorod, Russia
Russia Novosibirsk, Russia
Russia Perm, Russia
Russia Saint-Petersburg, Russia
Russia Sochi, Russia
Russia Surgut, Russia
Russia Syktyvkar, Russia
Russia Tomsk, Russia
Russia Ufa, Russia
Russia Vologda, Russia
Russia Yaroslavl, Russia
Russia Yuzhno-Sakhalinsk, Russia